

Study ID	Test(s)	No. analysed	No. with PC	Prevalence (%)	Median (range) Gleason score	Percentage with Gleason score ≥ 7
Amsellem-Ouazana 2005 ⁷⁴	T2-MRI/MRS	42	15	35.7	6.6 (5–9)	NR
Bhatia 2007 ⁷⁶	T2-MRI/MRS	21	2	9.5	(6, 6)	0.0
Cheikh 2009 ⁷⁸	T2-MRI/DCE	93	23	24.7	6 (5–9)	30.4
Cirillo 2008 ⁷⁹	T2-MRI/MRS	54	17	31.5	6 (4–8)	29.4
De la Rosette 2009 ⁸⁰	TRUS	139	20	14.4	6 (4–8)	NR
Djavan 2001 ⁸¹	TRUS	820	123	15.0	See notes	NR
Engelhard 2006 ⁸²	T2-MRI	37	14	37.8	4.5 (3–7)	21.4
Eskicorapci 2007 ⁸³	TRUS	211	54	25.6	See notes	NR
Franiel 2011 ⁸⁴	T2-MRI/MRS/DCE/DW	54	21	38.9	6 (6–10)	47.6
Hambrock 2010 ⁸⁶	T2-MRI/DCE/DW	68	40	58.8	6 (5–9)	20.3
Hoeks 2012 ⁸⁷	T2-MRI/DCE/DW	264	117	44.3	NR	NR See notes
Lattouf 2007 ⁹⁰	T2-MRI/DCE	26	14	53.8	6.5 (5–9)	50.0
Lin 2008 ⁹¹	TRUS	366	47	12.8	6.7 (SD 1.0) 7.6 (SD 1.3)	NR
Panebianco 2011 ⁹⁵	MRS/DCE	41	28	68.3	NR	46.4
Park 2008 ⁹⁶	DW-MRI	43	17	39.5	7 (6–9)	NR
Pepe 2010 ⁹⁷	TRUS	423	82	19.4	See notes	NR
Philip 2006 ⁹⁸	TRUS	241	42	17.4	6.5 (6–8)	NR
Quinlan 2009 ¹⁰²	TRUS	111	27	24.3	See notes	NR
Roehl 2002 ¹⁰³	TRUS	634	188	29.7	See notes	23.0
Roethke 2011 ¹⁰⁴	T2-MRI/MRS/DCE/DW	100	52	52.0	7 (5–9)	59.7
Sciarra 2010 ¹⁰⁵	MRS/DCE	90	44	48.9	NR	61.6
Testa 2010 ¹⁰⁶	T2-MRI/MRS	54	22	40.7	6 (1–9)	27.3
Wetter 2005 ¹⁰⁸	T2-MRI/MRS	6	2	33.3	(6, 7)	50.0
Yakar 2011 ¹⁰⁹	T2-MRI/DCE/DW	9	5	55.6	7 (6–8)	66.7
Yanke 2006 ¹¹⁰	TRUS	416	144	34.6	See notes	51.0
Yao 2009 ¹³⁶	T2-MRI	41	15	36.6	NR	NR See notes

Study ID	Test(s)	No. analysed	No. with PC	Prevalence (%)	Median (range) Gleason score	Percentage with Gleason score ≥ 7
Yuen 2004 ¹¹¹	TRUS	57	15	26.3	5.4 (2.5–6.0) 6.8 (4.0–8.0)	NR
Yuen 2004 ¹¹²	T2-MRI/MRS	24	7	29.2	6 (6–7)	42.9
Zackrisson 2004 ¹¹³	TRUS	706	169	23.9	See notes	NR

MRGB, MR-guided biopsy; NR, not reported; TCCL, total cancer core length.

Notes

Amsellem-Ouazana 2005:⁷⁴ mean Gleason score reported.

Djavan 2001:⁸¹ mean (SD) Gleason biopsy scores: biopsy 2, 5.7 (0.5); biopsy 3, 4.6 (0.4); biopsy 4, 4.4 (0.7). Mean (SD) Gleason radical prostatectomy scores: biopsy 2, 4.9 (0.8), biopsy 3, 4.2 (0.3); biopsy 4, 4.0 (0.4).

Eskicorapci 2007:⁸³ 35 men underwent radical prostatectomy. 32/35 had clinically important cancer (T2a, $n = 7$; T2b, $n = 20$; T3a, $n = 6$; T3b, $n = 2$).

Hoeks 2012:⁸⁷ when prostatectomy was not performed, clinical significance of MRGB-detected prostate cancer was defined by (1) a PSA level > 10 ng/ml and a PSA density > 0.15 ng/ml per ml; (2) clinical stage \geq T2b; (3) a Gleason grade 4 or 5 within the biopsy specimen; or (4) a TCCL ≥ 10 mm, where TCCL is the total cancer length in all MRGB cores from one cancer-suspicious region (definition based on Epstein and D'Amico criteria). In case of performed prostatectomy, PC was considered clinically significant when PC volume was ≥ 0.5 ml or a stage \geq pT3 or a Gleason grade 4 or 5 was present. Hoeks *et al.*⁸⁷ reported that the majority of detected cancers were clinically significant: a total of 87% (94 of 108) met the clinical criteria and 93% (26 of 28) met radical prostatectomy specimen criteria.

Lin 2008:⁹¹ reported Gleason scores as mean plus SD [6.7 (SD 1.0) for the second session and 7.6 (SD 1.3) for the third session].

Pepe 2010:⁹⁷ mean (range) Gleason scores: PZ cancer ($n = 76$) 6.5 (6–8); PZ + TZ cancer ($n = 4$) 6.8 (6–8); TZ cancer ($n = 2$) 6.

Philip 2006:⁹⁸ mean (range) Gleason score reported. All but three had a Gleason score ≥ 6 .

Quinlan 2009:¹⁰² mean (range) Gleason scores reported by biopsy number: biopsy 1, 6.1 (6–8); biopsy 2, 6.5 (6–7); biopsy 3, 6.25 (6–7); biopsy 4, 6.3 (6–7).

Roehl 2002:¹⁰³ Gleason 2–4: $n = 48$ (8%); Gleason 5–6: $n = 397$ (69%); Gleason 7: $n = 107$ (19%); Gleason 8–10: $n = 25$ (4%).

Yakar 2011:¹⁰⁹ Gleason scores reported are for six cancer-suspicious regions of five patients.

Yanke 2006:¹¹⁰ Gleason 4 to 6: $n = 30$ (49%); Gleason 7: $n = 26$ (43%); Gleason 8–10: $n = 5$ (8%).

Yao 2009:¹³⁶ reported that cancers detected by MRI were generally clinically significant with a Gleason score > 6 in 10 of 12 tumours (83%).

Yuen 2004:¹¹¹ mean (range) Gleason score reported. Yuen *et al.* reported that the mean (range) Gleason score was 5.4 (2.5 to 6.0) for biopsy 2 and 6.8 (4.0 to 8.0) for biopsy 3.

Zackrisson 2004:¹¹³ number (%) of Gleason score ≤ 3 reported by biopsy: biopsy 1, $n = 322$ (84%); biopsy 2, $n = 104$ (87%); biopsy 3, $n = 32$ (97%); biopsy 4, $n = 5$ (83%).